Is Salarius Pharmaceuticals Inc (SLRX) Stock About to Get Hot Friday?

The market has been down on Salarius Pharmaceuticals Inc (SLRX) stock recently. SLRX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Salarius Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SLRX!

See Full SLRX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SLRX Stock Today?

Salarius Pharmaceuticals Inc (SLRX) stock is unchanged 0% while the S&P 500 is down -0.68% as of 10:48 AM on Friday, Sep 17. SLRX is unmoved $0.00 from the previous closing price of $1.02 on volume of 155,692 shares. Over the past year the S&P 500 is up 31.25% while SLRX is up 14.61%. SLRX lost -$0.36 per share in the over the last 12 months. To screen for more stocks like Salarius Pharmaceuticals Inc click here.

More About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing effective treatments for cancers with high, unmet medical need. It is engaged in developing treatments for cancers caused by dysregulated gene expression. The company's lead epigenetic-based technology, seclidemstat (SP-2577) is a small molecule, administered orally, that inhibits the epigenetic enzyme lysine specific demethylase 1. Click Here to get the full Stock Report for Salarius Pharmaceuticals Inc stock.